Effect of Shenmai Injection on Immunologic Function in Stomach Cancer Patients after Chemotherapy) on Immunologic Function in Stomach Cancer Patients after Chemotherapy

Sheng-You Lin,Lu-Ming Liu,Liang-Cun Wu,Wei-Shun Zhou,Yong Guo,Min-He Shen,Wei-Hong Yang,Chang-Sheng Xie,Liang-Liang Chen,Pei-Fang Feng
DOI: https://doi.org/10.1007/bf02934248
IF: 2.9
1996-01-01
Chinese Journal of Integrative Medicine
Abstract:Sixty-three cases with stomach cancer were randomized into 2 groups and observed, the results showed that the count of T lymphocytes in chemotherapy combined with Shenmai injection (SMI) group increased, while in the control group it decreased, the difference being quite significant (P<0.05). The results also showed that the count of OKT1 cells and the OKT4/OKT8 ratio decreased after chemotherapy, but in SMI group both parameters increased in advance, which were higher in the 4th week after chemotherapy than that before chemotherapy. However in the meantime, the count of OKT1 cells and OKT4/OKT8 ratio of control group were still in low level. After chemotherapy the serum interleukin-2 receptor (sIL-2R) level also decreased (P<0.05), while activities of natural killer cell (NK) and lymphokine activated killer cell (LAK) level increased (P<0.05) in SMI group. But in the control group, although the sIL-2R level had no change, both NK and Lak level decreased significantly (P<0.05). In addition, the difference of IgA, IgM, IgG levels was not significant between these two groups. These results suggested that SMI might improve human immunologic function to facilitate the chemotherapy of patients with stomach cancer.
What problem does this paper attempt to address?